Antibody Therapy in Non-Hodgkin’s Lymphoma: The Role of Rituximab, 90Y-Ibritumomab Tiuxetan, and Alemtuzumab

  • Thomas Fietz
  • Eckhard Thiel
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 176)

Abstract

Targeting cancer cells with monoclonal antibodies has become an indispensable part of modern treatment against hematologic malignancies. The excitement of the first successful experimental results could be confirmed by large multicenter trials, thus paving the way for new approaches in first-line, relapse, and maintenance therapy. Three antibodies—rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab—are in clinical use worldwide and are reviewed in this chapter with a focus on practical information and fundamental principles of antibody-based therapy.

Keywords

Clin Oncol Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Aggressive Lymphoma Indolent Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ansell SM, Schilder RJ, Pieslor PC, et al (2004) Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin’s lymphoma: a review of the literature. Clin Lymphoma 5:202–204PubMedGoogle Scholar
  2. Berinstein NL, Grillo-López AJ, White CA, et al (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 9:995–1001PubMedCrossRefGoogle Scholar
  3. Cartron G, Watier H, Golay J, et al (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104:2635–2642PubMedCrossRefGoogle Scholar
  4. Cheson BD (2005) The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. BioDrugs 19:309–322PubMedCrossRefGoogle Scholar
  5. Cheson BD (2006) Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother 55:188–196PubMedCrossRefGoogle Scholar
  6. Coiffier B (2004) Effective immunochemotherapy for aggressive non-Hodgkin’s lymphoma. Semin Oncol 31[Suppl 2]:7–11PubMedCrossRefGoogle Scholar
  7. Coiffier B, Haioun C, Ketterer N, et al (1998) Rituximab (anti CD-20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study. Blood 92:1927–1932PubMedGoogle Scholar
  8. Coiffier B, Lepage E, Briere J, et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242PubMedCrossRefGoogle Scholar
  9. Czuczman M, Emmanouilides C, Witzig T, et al (2002) Multivariate analysis of prognostic factors correlated with response to 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkins lymphoma. Proc Am Soc Clin Oncol 21:abstr 1062Google Scholar
  10. DeMonaco N, Wu M, Osborn J (2005) Phase II trial of abbreviated CHOP-rituximab followed by 90Y ibritumomab tiuxetan (Zevalin) and rituximab in patients with previously-untreated follicular non-Hodgkin lymphoma (NHL). Blood 106:abstr 2449Google Scholar
  11. Ely P, Stearns D, Zaki B, et al (2005) Successful PBSC mobilization, collection, transplantation and engraftment after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin’s lymphoma (NHL). Blood 106:abstr 5517Google Scholar
  12. Emmanouilides C, Murray J, Vo K, et al (2003) Earlier treatment with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkins lymphoma (NHL): results with second-line therapy. Blood 102:abst 4949Google Scholar
  13. Feugier P, Van Hoof A, Sebban C, et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23:4117–4126PubMedCrossRefGoogle Scholar
  14. Fietz T, Rieger K, Schmittel A, et al (2004) Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment. Hematol J 5:451–452PubMedCrossRefGoogle Scholar
  15. Fietz T, Uharek L, Gentilini C, et al (2006) Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma 47:59–63PubMedCrossRefGoogle Scholar
  16. Fisher RI, Gaynor ER, Dahlberg S, et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for ad vanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006PubMedCrossRefGoogle Scholar
  17. Fisher RI, LeBlanc M, Press OW, et al (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447–8452PubMedCrossRefGoogle Scholar
  18. Ghielmini M, Schmitz SF, Cogliatti SB, et al (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416–4423PubMedCrossRefGoogle Scholar
  19. Ghielmini M, Schmitz SF, Cogliatti S, et al (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23:705–711PubMedCrossRefGoogle Scholar
  20. Gordan LN, Grow WB, Pusateri A, et al (2005) Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. Clin Oncol 23:1096–1102CrossRefGoogle Scholar
  21. Gordon LI, Witzig T, Molina A, et al (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5:98–101PubMedGoogle Scholar
  22. Groot MT, Lugtenburg PJ, Hornberger J, et al (2005) Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol 74:194–202PubMedCrossRefGoogle Scholar
  23. Habermann TM, Weller E, Morrison VA, et al (2004) Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood 104:abstr 127Google Scholar
  24. Hainsworth JD, Litchy S, Burris HA 3rd, et al (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J Clin Oncol 20:4261–4267PubMedCrossRefGoogle Scholar
  25. Hainsworth JD, Litchy S, Shaffer DW, et al (2005) Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma— a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23:1088–1095PubMedCrossRefGoogle Scholar
  26. Hale G, Waldmann H (2000) From laboratory to clinic: the story of CAMPATH-1. Methods Mol Med 40:243–266Google Scholar
  27. Herold M, Pasold R, Srock S, et al (2004) Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin’s lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood 104:abstr 584Google Scholar
  28. Hiddemann W, Kneba M, Dreyling M, et al (2005a) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725–3732PubMedCrossRefGoogle Scholar
  29. Hiddemann W, Forstpointner R, Dreyling M, et al (2005b) Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Proc Am Soc Clin Oncol 23:Abstr 6527Google Scholar
  30. Hieke K, Pasold R, Neser S, et al (2004) Cost evaluation of rituximab plus MCP vs. MCP alone in advanced stage indolent non-Hodgkin’s-lymphoma based on a randomized controlled multicenter trial. Blood 104:Abstr 87Google Scholar
  31. Huhn D, von Schilling C, Wilhelm M, et al (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326–1331PubMedCrossRefGoogle Scholar
  32. Keating MJ, O’Brien S, Albitar M, et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Clin Oncol 23:4079–4088CrossRefGoogle Scholar
  33. Khouri IF, Saliba RM, Hosing C, et al (2005) Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin’s lymphomas. J Clin Oncol 23:2240–2247PubMedCrossRefGoogle Scholar
  34. Kiewe P, Jahnke K, Maza S, et al (2006) Yttrium-90-ibritumomab tiuxetan (Zevalin) for primary CNS lymphoma: encouraging response data in an innovative prospective therapeutic trial. 44th Annual Convention of the German Society for Nuclear Medicine. Schattauer Verlag, Stuttgart, V133Google Scholar
  35. Liu N, Keating M, Albitar M, et al (2003) Yttrium-90 ibritumomab tiuxetan for minimal residual disease in CLL. Blood 102:Abstr 2498Google Scholar
  36. Lundin J, Kimby E, Bjorkholm M, et al (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768–773PubMedCrossRefGoogle Scholar
  37. Maloney DG (2005) Treatment of follicular non-Hodgkin’s lymphoma. Curr Hematol Rep 4:39–45PubMedGoogle Scholar
  38. Marcus R, Imrie K, Belch A, et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417–1423PubMedCrossRefGoogle Scholar
  39. Micallef IN (2004) Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin’s lymphoma. Clin Lymphoma 5[Suppl 1]:27–32CrossRefGoogle Scholar
  40. Moreton P, Kennedy B, Lucas G, et al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Clin Oncol 23:2971–2979CrossRefGoogle Scholar
  41. O’Brien S, Kantarjian H, Thomas DA, et al (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165–2170PubMedGoogle Scholar
  42. Orina JN, Moore S, Lechowicz M, et al (2005) Systematic review and meta-analysis of radioimmunotherapy regimens in patients with relapsed follicular and transformed non Hodgkins lymphomas. Blood 106:Abstr 3113Google Scholar
  43. Pfreundschuh M, Truemper L, Gill D, et al (2004) First analysis of the completed Mabthera International (Mint) Trial in Young Patients with Low-Risk Diffuse Large B-Cell Lymphoma (DLBCL): addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identifi-cation of a very favorable subgroup with IPI=O and no bulky disease. Blood 104:Abstr 157Google Scholar
  44. Pfreundschuh M, Kloess M, Schmits R, et al (2005) Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 106:Abstr 13Google Scholar
  45. Rieger K, Von Grunhagen U, Fietz T, et al (2004) Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia—change of regimen needed? Leuk Lymphoma 45:345–349PubMedCrossRefGoogle Scholar
  46. Robak T (2005) Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs 19:9–22PubMedCrossRefGoogle Scholar
  47. Stern M, Herrmann R (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 54:11–29PubMedGoogle Scholar
  48. Theuer CP, Leigh BR, Multani PS, et al (2004) Radioimmunotherapy of non-Hodgkin’s lymphoma: clinical development of the Zevalin regimen. Biotechnol Annu Rev 10:265–295PubMedGoogle Scholar
  49. Thieblemont C, Boufia F, Hornez E, et al (2004) Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-CLL/SLL. Leuk Lymphoma 45:711–714PubMedCrossRefGoogle Scholar
  50. Thieblemont C, Roch H, Boubacari AT, et al (2005) Maintenance alemtuzumab in refractory B-cell chronic lymphocytic leukemia patients: updated data. Blood 106:Abstr 5032Google Scholar
  51. Van Oers M, Glabbeke M, Teodorovic I, et al (2004) Chimeric anti-CD20 monoclonal antibody (rituximab; Mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma:a phase III randomized intergroup clinical trial. Blood 104:Abstr 586Google Scholar
  52. Wendtner CM, Ritgen M, Schweighofer CD, et al (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18:1093–1101PubMedCrossRefGoogle Scholar
  53. Witzig TE, Gordon LI, Cabanillas F, et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20: 2453–2463PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • Thomas Fietz
    • 1
  • Eckhard Thiel
    • 2
  1. 1.Hematology, Oncology and Transfusion MedicineCharité Campus Benjamin FranklinBerlinGermany
  2. 2.Medizinische Klinik III (Hematology, Oncology and Transfusion Medicine)Charité Campus Benjamin FranklinBerlinGermany

Personalised recommendations